News | November 17, 2008

Ascent Receives 510(k) Clearance for Reprocessed Biosense Webster LASSO Circular Mapping Catheters

November 18, 2008 - Ascent Healthcare Solutions, said yesterday it received the industry's first 510(k) clearance from the FDA to reprocess the LASSO 2515 Variable Circular Mapping Catheter manufactured by Biosense Webster.

With this new clearance, Ascent continues to increase its portfolio of EP catheters to offer EP cath labs the ability to most effectively manage their resources while ensuring that clinicians have access to their preferred device to most effectively diagnose arrhythmias, the company said.

The average price for these reprocessed circular mapping catheters is $700; a savings of 53-58 percent, compared with the national average cost of $1,500-$1,650 when these devices are purchased directly from the original manufacturer. Ascent's focus on providing reprocessing and remanufacturing services for a wide range of high-cost, high-volume devices enables its hospital partners to reallocate its savings to staffing, services and technology that improve patient care. Hospitals using Ascent's services also help protect the environment through reprocessing, recycling and material reclamation, the company said.

The Biosense Webster LASSO 2515 Variable Circular Mapping Catheter has been designed to facilitate electrophysiological mapping of the atria of the heart and is deployed in the right or left atrium. The catheter features a variable loop that easily adjusts to any vein sized between 25 and 15 mm. Its adjustable tip provides efficient mapping and is also deflectable for maximum movement. It is available in 10 and 20-electrode configurations. These devices will be the first line of reprocessed diagnostic EP catheters to be packaged in Ascent's thermoformed tray.

For more information: www.ascenths.com

Related Content

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT)| January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT)| May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT)| April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT)| March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
Overlay Init